Autopsy report · NCT00670748
Chemotherapy Followed by ESO-1 Lymphocytes and Aldesleukin to Treat Metastatic Cancer
Cause of deathOther
“A more highly selected protocol with ESO TCR opened for pts with melanoma”
Life of this trial
- Ran for about 8 years 1 month before it stopped.
- 45 participants enrolled.
- Results were posted on the registry.
Vital statistics
- Status
- Terminated
- Phase
- Phase 2
- Sponsor
- National Cancer Institute (NCI)
- Sponsor type
- US National Institutes of Health
- Conditions
- Metastatic Melanoma; Metastatic Renal Cell Cancer; Metastatic Cancer
- Interventions
- Anti-NY ESO-1 T-cell receptor PBL; aldesleukin; Cyclophosphamide; fludarabine phosphate; ALVAC NY ESO-1 vaccine
- Participants
- 45
- Sites
- 1
- Countries
- United States
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.